CA Patent

CA2551999C — Device of miniaturised construction for producing high pressure in a fluid to be atomised

Assigned to Boehringer Ingelheim International GmbH · Expires 2010-12-14 · 15y expired

What this patent protects

A miniaturised device for producing high pressure in a fluid imposes stringent requirements on the manufacturing process. The device according to the invention consists of a hollow piston (57) displaceably mounted in a cylinder and a valve member (58) which is guided by the hollo…

USPTO Abstract

A miniaturised device for producing high pressure in a fluid imposes stringent requirements on the manufacturing process. The device according to the invention consists of a hollow piston (57) displaceably mounted in a cylinder and a valve member (58) which is guided by the hollow piston (57) and mounted so as to be axially movable relative to the hollow piston (57). The valve member (58) is arranged at one end of the hollow piston (57) inside or immediately in front of the end of the hollow piston (57). The device is used in a mechanically operated high pressure atomiser. This consists of a two- part housing which comprises a pump housing (52) with nozzle (54), a blocking mechanism (62), a spring housing (67) with spring (68), a non-pressurised storage container (71) for the fluid (72) and a mechanical counter integrated in the spring housing (67). The valve (58) operates without any auxiliary force, closes very rapidly and is sealed tight against high pressure. The atomiser is safe and simple to operate and environmentally friendly. The fluid is metered extremely accurately. The atomiser is used, for example, to product an inhalable aerosol of a liquid medicament without the use of a propellant gas, at 320 bar. for example.

Drugs covered by this patent

Patent Metadata

Patent number
CA2551999C
Jurisdiction
CA
Classification
Expires
2010-12-14
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.